AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00552591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week risk reduction program, managed by a Heart Health Educator
Description: The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
Study NCT00540566 — intervention group
Intervention type: DEVICE
Intervention: Optical Biopsy imaging
Description: Optical Biopsy imaging
Study NCT01084772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VISIONAIRE Total Knee Arthroplasty
Description: TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
Study NCT01084772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Total Knee Arthroplasty
Description: TKA will be performed with standard instrumentation, depending on randomization assignment.
Study NCT02442037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC group
Description: Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.
Study NCT02442037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group(Normal saline)
Description: Normal saline in same volume as MSCs are transplanted to patients.
Study NCT03167008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: semen sample
Description: -Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
Study NCT03167008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
Study NCT01867307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Study NCT01867307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: open label
Study NCT04439825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Neurotoxin
Description: glabella, forehead lines and/or lateral canthal lines
Study NCT04439825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (preservative free)
Study NCT00234676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin ®
Description: Premarin ® 0.625 mg per day orally
Study NCT03838575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% alcoholic chlorhexidine skin prep (SKIN PREP)
Description: This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
Study NCT03838575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 2% alcoholic chlorhexidine skin prep (SKIN PREP)
Description: This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
Study NCT03838575 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Iodophor Antimicrobial Incise Drapes (DRAPE)
Description: Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied.
Study NCT03838575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin-impregnated implants/ sponges (SPONGE)
Description: This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
Study NCT03838575 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gentamicin-impregnated implants/ sponges (SPONGE)
Description: This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
Study NCT03838575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NONE (Control)
Description: Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used.
Study NCT03357237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: medical device
Description: patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo
Study NCT03357237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical device
Description: patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo
Study NCT02365740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric emptying test
Description: gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
Study NCT02365740 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: gastric emptying test
Description: gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
Study NCT02365740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gut hormones determination
Description: blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
Study NCT02365740 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: gut hormones determination
Description: blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
Study NCT01519882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day.
Study NCT01519882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day.
Study NCT04218877 — intervention group
Intervention type: OTHER
Description: There will be no intervention, only observation
Study NCT02365740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: 7 days Continuous Glucose Monitoring
Study NCT02365740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin single bolus
Description: pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
Study NCT01009359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 DPA-714 (BAY85-8102)
Description: Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
Study NCT01009359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 DPA-714 (BAY85-8102)
Description: Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
Study NCT01009359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 DPA-714 (BAY85-8102)
Description: Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
Study NCT04305496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
Study NCT04305496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
Study NCT04305496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study NCT04305496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study NCT04267952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention program developed according to planned behavior theory
Description: The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
Study NCT04267952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classical hand hygiene education
Description: expression of hand hygiene with verbal presentation method in a 40-minute lecture
Study NCT00940316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given intravenously 6mg/kg every 2 weeks
Study NCT00940316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally 150mg daily
Study NCT02365740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin double-wave bolus
Description: pre-prandial insulin fractioned into a double-wave bolus
Study NCT04303247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted CAR-T cells
Description: The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
Study NCT00453453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide given orally in the emergency department
Study NCT00137267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time limited case management
Description: This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
Study NCT00137267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
Study NCT04770701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ahah Drug
Description: - Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Study NCT04770701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahah Placebo
Description: - Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months.
Study NCT00934752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Paclitaxel-Coated Balloon
Description: Percutaneous transluminal coronary angioplasty (PCTA)
Study NCT06331806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Evaluation of myocardial fibrosis
Description: echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
Study NCT01650610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training executive functions tasks
Description: The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
Study NCT02210832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: financial incentives
Description: financial incentives provided contingent on biochemically confirmed smoking abstinence
Study NCT01806064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105 and Axitinib
Study NCT01806064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Study NCT04377477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single fraction whole lung radiotherapy
Description: Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
Study NCT02258230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mode of the 3D Laparoscopic Video System
Description: Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
Study NCT00940316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
Study NCT00645892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
Study NCT00645892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
Study NCT03647670 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
Study NCT03647670 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
Study NCT02258230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mode of the 3D Laparoscopic Video System
Description: Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
Study NCT01330966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
Study NCT02052193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Measurement of toxicity related to UV exposure
Study NCT00690092 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Spherule-derived coccidioidin
Description: 1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
Study NCT01722292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Administered orally
Study NCT01722292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study NCT02299986 — intervention group
Intervention type: OTHER
Intervention: Ultrasound measurement
Description: Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
Study NCT03477227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short stocking
Description: Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
Study NCT03477227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual stocking
Description: Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
Study NCT01585623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT01585623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazol
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT01585623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01585623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Pharmaceutical form:solution~Route of administration: oral
Study NCT01090258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamilton ventilator (G5 modify to S1) Automated settings
Description: Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
Study NCT01090258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton ventilator (G5) protocolized settings
Description: Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
Study NCT01049490 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: S-OIV H1N1 vaccine
Description: Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
Study NCT02052193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Measurement of toxicity related to UV exposure
Study NCT02052193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Measurement of toxicity related to UV exposure
Study NCT01722292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Administered IV
Study NCT01722292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered IV
Study NCT01722292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Administered IV